Synthesis of Some Fused Triazole Derivatives Containing 4-Isobutylphenylethyl and 4-Methylthiophenyl Moieties

Manjunatha Kumsi^a, Boja Poojary^a, Prajwal L. Lobo^a, Jennifer Fernandes^b, and Chandrashekhar Chikkanna^c

^a Department of Chemistry, Mangalore University, Mangalagangothri-574199, Karnataka, India

Reprint requests to Dr. Boja Poojary. Fax: +91-824-2287367. E-mail: bojapoojary@gmail.com

Z. Naturforsch. 2010, 65b, 1353 – 1358; received July 17, 2010

A series of substituted [1,3]thiazolo[3,2-*b*][1,2,4]triazole derivatives **4** were synthesized in good yield by condensing 2-substituted-1,2,4-triazole-5-thiols **3** with various *N*-aryl-maleimides in acetic acid media. All structures of the newly synthesized compounds were elucidated by elemental analyses and spectral data.

Key words: 1,2,4-Triazole-5-thiol, N-Aryl-maleimides, [1,3]Thiazolo[3,2-b][1,2,4]triazoles

Introduction

Non-steroidal anti-inflammatory drugs (NSAIDs) such as Ibuprofen are widely used for the treatment of pain, fever and inflammation [1-3]. Prostaglandins are important biological mediators of inflammation, originating from biotransformation of arachidonic acid catalyzed by cyclooxygenase [4]. In the early 1990s, it was discovered that the enzyme exists as two isoforms, one constitutive (COX-1) and the other inducible (COX-2) [5]. COX-1 is constitutively expressed and provides cytoprotection in the gastrointestinal (GI) tract, while COX-2 is inducible and mediates inflammation [4,6]. Prolonged use of NSAIDs like Ibuprofen has been associated with gastrointestinal complications ranging from stomach irritation to life-threatening gastrointestinal ulceration and bleeding [7,8]. Therefore the development of new NSAIDs without these side effects has long been awaited. Selective COX-2 inhibitors with better safety profile have been marketed as a new generation of NSAIDs [9]. Thus, there remains a compelling need for effective NSAIDs with an improved safety profile.

It has also been reported that the presence of the 4-methylthiophenyl moiety [10] is found to increase the biological activity of the molecules. A few heterocyclic analogs containing *N*-bridged heterocycles bearing the 4-methylthiophenyl moiety possess good anti-inflammatory [10, 11] and antimicrobial [12, 13] activities.

1,2,4-Triazole derivatives due to their wide range of biological activities such as antimicrobial, antiinflammatory [14], anticancer [15], antitubercular [16] and antimycotic [17, 18] properties have received considerable attention. 1,2,4-Triazole rings have been incorporated into a variety of therapeutically interesting drug candidates such as Triazolam [19], Alprazolam [20], Etizolam [21], Furacyclin [22], and Ribavirin [23].

On the other hand, thiazoles have attracted continuing interest because of their varied biological activities [27–32]. There are also some drugs containing the thiazole moiety, for example: Fentiazac, Meloxicam [24, 25] (both anti-inflammatory agents), Nizatidine [26] (antiulcerative agent), and Sulfathiazole [26] (antimicrobial agent).

In view of these marked applications of [1,2,4]triazoles and [1,3]thiazoles, it was envisaged that chemical entities containing both of these moieties would result in compounds of interesting biological activities. It was considered to synthesize some substituted [1,3]thiazolo[3,2-b]-1,2,4-triazoles incorporating 2-(4-isobutylphenyl)ethyl and 4-methylthiophenyl moieties.

Results and Discussion

A synthetic approach to the title compounds is outlined in Scheme 1. The acid hydrazides **2** were prepared by the esterification of 2-(4-isobutylphenyl)propanoic acid and 4-methylthiophenyl acetic acid

0932-0776 / 10 / 1100-1353 \$ 06.00 © 2010 Verlag der Zeitschrift für Naturforschung, Tübingen · http://znaturforsch.com

b Department of Pharmachemistry, NGSM College of Pharmacy, Panner, Deralakatte-574 160, Karnataka, India

^c Department of Medicinal Chemistry, SDM College, Ujire-574162, Karnataka, India

 $R = CH_2CH(CH_3)_2$, SCH_3 ; $R^1 = CH_3$, H; $R^2 = H$, 3-Cl-4-F, 4-F, 4-Cl, $4-CH_3$, $4-OCH_3$, 4-Br

	4a	4b	4c	4d	4e	4f	4g
R	CH ₂ CH(CH ₃) ₂						
\mathbb{R}^1	CH ₃	CH_3	CH_3	CH_3	CH_3	CH_3	CH_3
\mathbb{R}^2	H	3-Cl-4-F	4-F	4-Cl	4-CH ₃	4-OCH ₃	4-Br
	4h	4i	4j	4k	41	4m	4n
R	4h SCH ₃	4i SCH ₃	4j SCH ₃	4k SCH ₃	4I SCH ₃	4m SCH ₃	4n SCH ₃
R R ¹	SCH ₃		Ů.		4I SCH ₃ H		

Scheme 1.

followed by treatment with hydrazine hydrate in absolute alcohol [33]. The resulting acid hydrazides on reaction with potassium thiocyanate in the presence of conc. hydrochloric acid yielded the corresponding thiosemicarbazides, which on cyclization with an aqueous 5 % NaOH solution afforded 3-substituted-[1,2,4]triazole-5-thiols 3. Condensation of these triazoles with various substituted N-aryl-maleimides in acetic acid media yielded 2-(2-substituted-6-oxo-5,6-dihydro[1,3]thiazolo[3,2-b][1,2,4]triazol-5-yl)-N-aryl-acetamides 4. The substituted N-aryl-maleimides were prepared according to the literature procedures [34]. The formation of fused thiazotriazoles 4a - n has been confirmed by the elemental analyses and spectral data of the products.

In the IR spectra of $\bf 3a$ and $\bf 3b$, absorption bands due to an amide carbonyl function in the region $1760-1705~\rm cm^{-1}$ and to the NH-NH₂ moiety in the region $3455-3203~\rm cm^{-1}$ of their precursors were found to be absent. However, they showed a new absorption band at $3114~\rm cm^{-1}$ of an NH group supporting their formation.

The IR spectra of thiazolotriazoles **4** showed the absorption bands corresponding to their C=O and C=N

groups in the region 1710–1725 cm⁻¹ and 1585–1610 cm⁻¹, respectively, thus indicating their formation from **3** through cyclocondenzation with *N*-arylmaleimides.

The 1 H NMR spectrum of 1,2,4-triazole-5-thiol $\bf 3a$ showed a downfield, broad singlet at $\delta=12.64$ ppm for the D₂O-exchangeable NH and SH protons. The downfield shift of this signal indicates tautomerism in the triazole ring. Two distinct doublets at $\delta=0.85$ (J=8.0 Hz) and $\delta=1.68$ (J=8.0 Hz) were observed for the methyl protons. The isopropyl methyne proton was observed as a multiplet in the range $\delta=1.80-1.88$ ppm, and the other methyne proton was observed as a quartet at $\delta=4.14$ ppm. The methylene protons resonated as a doublet at $\delta=2.45$ ppm (J=4.0 Hz). The aromatic protons appeared as two doublets at $\delta=6.97$ and 7.06 ppm with J=8.0 Hz. Further, an LC-MS spectrum of $\bf 3a$ showed the molecular ion peak at m/z=261, in conformity with its molecular formula, $C_{14}H_{19}N_3S$.

The 1H NMR spectrum of **3b** also showed a downfield broad singlet at $\delta = 13.30$ ppm corresponding to its D₂O-exchangeable NH and SH protons. Two singlets at $\delta = 2.41$ ppm and $\delta = 3.83$ ppm have been attributed to the SCH₃ and CH₂ protons. The four aro-

matic protons of the 4-methylthiophenyl moiety resonated as two doublets at $\delta = 7.18$ and 7.20 ppm (J = 8.3 Hz), respectively. Further, an LC-MS spectrum of **3b** showed the molecular ion peak at m/z = 237, in conformity with its molecular formula, $C_{10}H_{11}N_3S_2$.

In the ${}^{1}H$ NMR spectra of compounds 4a - n, protons of a CH2-CH fragment showed the characteristic pattern of an ABX system. The chemical shifts of the protons H^A , H^B and H^X are at $\delta \sim 3.32$ 3.38, $\sim 2.81-2.95$ and $\sim 4.55-4.65$ ppm, respectively. Large values of $J_{AB} = 12.0 - 18.0$ Hz, $J_{AX} =$ 7.5-9.0 Hz and $J_{\text{BX}} = 4.0-8.0$ Hz were observed like in the structurally related 2-thioxo-4-thiazolidinones, referred to a "carbonyl effect" by Takahashi [35]. The acetamide NH proton appeared as a sharp singlet at δ = 13.80-14.10 ppm. In the 13 C NMR spectra of 4 the acetamide carbonyl carbon and the thiazolidinone carbonyl carbon atoms appeared in the region $\delta = 172.1$ – 174.2 and 176.2 – 177.8 ppm, respectively, in addition to other characteristic signals of the remaining carbon atoms.

Experimental Section

Instruments and starting materials

The melting points were determined by an open capillary method and are uncorrected. The IR spectra (from KBr pellets) were recorded on a Shimadzu FT-IR 157 spectrophotometer. The ¹H NMR and ¹³C NMR spectra were recorded on a Brukar Avance II-400 (400 MHz) spectrometer using TMS as an internal standard. Mass spectra were recorded in an Agilent Technology LC-mass spectrometer. The accelerating voltage was 10 kV, and spectra were recorded at r.t. Elemental analyses (CHNS) were performed on the CHNS analyzer. The progress of the reaction was monitored by thin-layer chromatography (TLC) on silica gel plates.

General procedure for the preparation of acid hydrazides 2a, b

The mixture of ethyl esters of substituted aromatic acids 1 (0.1 mol) and hydrazine hydrate (0.2 mol) was refluxed in absolute alcohol (50 mL) for 8 h. The excess solvent was then distilled off under reduced pressure, and the concentrated solution was quenched by its addition to ice cold water. The solid separated was filtered, washed and dried. The crude product was purified by recrystallization from ethanol.

2a: M. p. 71 °C; yield 85 %. – IR (KBr): v = 3449 (NH, NH₂), 3275 (NH₂), 2972 (C-H), 1695 (CO-NH) cm⁻¹. – ¹H NMR (CDCl₃): $\delta = 0.85$ (d, J = 8 Hz, 6 H, 2 × CH₃), 1.68 (d, J = 8 Hz, 3 H, CH₃), 1.80 – 1.88 (m, 1 H, CH), 2.45 (d, J = 4 Hz, 2 H, CH₂), 4.0 (s, 2 H, NH₂), 4.14 (q, J = 8 Hz, 1 H,

CH), 7.5 (br s, 5 H, C₆H₄ and NH). – LC-MS: m/z (%) = 220 (78) [M]⁺. – C₁₃H₂₀N₂O (220.3): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

2b: M. p. 136 °C; yield 86 %. – IR (KBr): v = 3344 (NH, NH₂), 3203 (NH₂), 2963 (C-H), 1622 (CO-NH) cm⁻¹. – ¹H NMR (CDCl₃): $\delta = 2.49$ (s, 3 H, SCH₃), 3.53 (s, 2 H, CH₂), 3.82 (br s, 2 H, NH₂), 6.67 (br s, 1 H, NH), 7.18 (d, J = 8.3 Hz, Ar-H), 7.26 (d, J = 8.3 Hz, Ar-H). – LC-MS: m/z (%) = 196 (90) [M]⁺. – C₉H₁₂N₂OS (196.2): calcd. C 55.09, H 6.16, N 14.27, S 16.34; found C 55.06, H 6.15, N 10.25, S 15.71.

General procedure for the preparation of 1,2,4-triazole-3-thiols **3a**, **b**

Aroyl hydrazide **2** (0.1 mol) was dissolved in water (100 mL) containing concentrated hydrochloric acid (10 mL). Potassium thiocyanate (0.2 mol) was added, and the mixture was warmed on a water bath for 5 h. The reaction mixture was cooled. The precipitated solid was filtered, dried and recrystallized from ethanol to get the aroyl thiosemicarbazide. A mixture of aroyl thiosemicarbazide (0.01 mol) and sodium hydroxide (5 %, 100 mL) was refluxed for 3 h. The reaction mixture was poured on crushed ice and acidified with dilute hydrochloric acid. The precipitate thus obtained was filtered, dried and recrystallized from ethanol.

3a: M. p. 198 °C; yield 85 %. – IR (KBr): v = 3100 (Ar-H), 2972 (C-H), 1215 (C=S) cm⁻¹. – ¹H NMR (CDCl₃): $\delta = 0.85$ (d, J = 8 Hz, 6 H, 2 × CH₃), 1.68 (d, J = 8 Hz, 3 H, CH₃), 1.80 – 1.88 (m, 1 H, CH), 2.45 (d, J = 4.0 Hz, 2 H, CH₂), 4.15 (q, J = 8.0 Hz, 1 H, CH), 697 (d, J = 8 Hz, 2 H, ArH), 706 (d, J = 8 Hz, 2 H, ArH), 12.64 (br s, 2 H, NH/SH). – ¹³C NMR ([D₆]DMSO): $\delta = 18.34$, 18.78, 22.42, 30.28, 37.48, 126.13, 126.32, 128.25, 128.43, 136.20, 139.05, 161.05, 167.15. – LC-MS: m/z (%) = 261 (86) [M]⁺. – C₁₄H₁₉N₃S (261.3): calcd. C 64.31; H 7.33; N 16.08; S 12.27; found C 64.30; H 7.33; N 16.09; S 12.27.

3b: M. p. 197 °C; yield 85 %. – IR (KBr): v = 3154 (NH), 1206 (C=S) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 2.49$ (s, 3 H, SCH₃), 3.83 (s, 2 H, CH₂), 7.18 (d, J = 8.36 Hz, Ar-H), 7.26 (d, J = 8.36 Hz, Ar-H), 13.30 (br s, 2 H, NH/SH). – ¹³C NMR ([D₆] DMSO): $\delta = 16.12$, 32.13, 127.51, 128.25, 131.99, 139.21, 152.16, 167.10. – LC-MS: m/z (%) = 237 (89) [M]⁺. – C₁₀H₁₁N₃S₂ (237.3): calcd. C 50.60, H 4.67, N 17.70, S 27.02; found C 50.56, H 4.71, N 17.79, S 27.05.

General procedure for the preparation of substituted [1,3]thiazolo[3,2-b][1,2,4]triazole derivatives 4a - n

A mixture of a 1,2,4-trizole-5-thiol (10 mmol) and the appropriate *N*-arylmaleimide (10 mmol) was refluxed for 2 h in 10 mL of glacial acetic acid. After cooling to r. t., the reaction mixture was poured into 50 mL of water. The precipitated colorless powder was filtered off, washed with methanol and recrystallized from ethanol.

4a: M. p. 157 °C; yield 85 %. – IR (KBr): v = 3126 (NH), 3022 (Ar-H), 2954 (C-H), 1715 (C=O), 1596 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 0.83$ (d, J = 8 Hz, 6 H, 2 × CH₃), 1.51 (d, J = 8 Hz, 3 H, CH₃), 1.74 – 1.81 (m, 1 H, CH), 2.38 (d, J = 8 Hz, 2 H, CH₂), 2.90 (dd, J = 16 Hz, 1 H), 3.37 (dd, J = 16, 8 Hz, 1 H), 4.19 (q, J = 4 Hz, 1 H, CH), 4.61 (dd, J = 8, 7, 4 Hz, 1 H), 7.05 (d, J = 8 Hz, 2 H, Ar-H), 7.08 (d, J = 8 Hz, 2 H, Ar-H), 7.12 – 7.74 (m, 5 H, phenyl), 13.93 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 18.8$, 19.2, 22.8, 30.6, 34.6, 37.7, 39.6, 127.4, 127.8, 129.8, 130.2, 139.0, 152.4, 169.5, 173.4, 179.7. – LC-MS: m/z (%) = 434 (55) [M]⁺. – C₂₄H₂₆N₄O₂S (434.5): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4b: M. p. 118 °C; yield 77 %. – IR (KBr): v = 3126 (NH), 3050 (Ar-H), 2956 (C-H), 1713 (C=O), 1584 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 0.83$ (d, J = 8 Hz, 6 H, 2 × CH₃), 1.50 (d, J = 8 Hz, 3 H, CH₃), 1.73 – 1.79 (m, 1 H, CH), 2.38 (d, J = 8 Hz, 2 H, CH₂), 2.91 (dd, J = 16 Hz, 1 H), 3.34 (dd, J = 16, 8 Hz, 1 H), 4.19 (q, J = 4 Hz, 1 H, CH), 4.60 (dd, J = 8, 7, 4 Hz, 1 H), 7.08 (d, J = 8 Hz, 2 H, Ar-H), 7.12 (d, J = 8 Hz, 2 H, Ar-H), 7.32 – 7.47 (m, 4 H, 3-chloro-4-fluorophenyl), 13.96 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 18.7$, 19.2, 22.8, 30.4, 34.5, 37.0, 39.8, 127.8, 128.5, 130.4, 132.0, 140.0, 153.1, 168.7, 173.2, 179.6. – LC-MS: m/z (%) = 486 (54) [M]⁺, 488 (18) [M]⁺. – C₂₄H₂₄N₄O₂CIFS (486.9): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4c: M. p. 124 °C; yield 72 %. – IR (KBr): v = 3128 (NH), 3058 (Ar-H), 2946 (C-H), 1703 (C=O), 1598 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 0.82$ (d, J = 8 Hz, 6 H, 2 × CH₃), 1.51 (d, J = 8 Hz, 3 H, CH₃), 1.74–1.81 (m, 1 H, CH), 2.38 (d, J = 8 Hz, 2 H, CH₂), 2.88 (dd, J = 16 Hz, 1 H), 3.39 (dd, J = 16, 8 Hz, 1 H), 4.18 (q, J = 4 Hz, 1 H, CH), 4.63 (dd, J = 8.7, 4 Hz, 1 H), 7.04–7.10 (m, 4 H, Ar-H), 7.26–7.38 (m, 4 H, 4-fluorophenyl), 13.99 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 18.7$, 19.2, 22.8, 30.4, 34.6, 37.2, 39.0, 126.6, 127.8, 129.6, 130.4, 141.2, 152.9, 168.1, 173.1, 179.5. – LC-MS: m/z (%) = 452 (72) [M]⁺. – C₂₄H₂₅N₄O₂FS (452.5): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4d: M. p. 170 °C; yield 85 %. – IR (KBr): v = 3130 (NH), 3068 (Ar-H), 2961 (C-H), 1710 (C=O), 1602 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 0.83$ (d, J = 8 Hz, 6 H, 2 × CH₃), 1.52 (d, J = 8 Hz, 3 H, CH₃), 1.76 – 1.82 (m, 1 H, CH), 2.38 (d, J = 8 Hz, 2 H, CH₂), 2.86 (dd, J = 16 Hz, 1 H), 3.35 (dd, J = 16, 8 Hz, 1 H), 4.19 (q, J = 4 Hz, 1 H, CH), 4.72 (dd, J = 8, 4 Hz, 1 H), 7.06 (d, J = 8 Hz, 2 H, Ar-H), 7.10 (d, J = 8 Hz, 2 H, Ar-H), 7.32 – 7.48 (m, 4 H, 4-chlorophenyl), 13.98 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 18.6$, 19.3, 22.8, 30.4, 34.5, 37.6, 40.3, 127.2, 128.4, 130.4, 132.1, 141.2, 153.4, 169.1, 173.4, 179.8. – LC-MS: m/z (%) = 468 (60) [M]⁺, 470 (20) [M]⁺. – C₂₄H₂₅N₄O₂ClS (468.9):

calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4e: M. p. 142 °C; yield 88 %. – IR (KBr): v = 3483 (NH), 3080 (Ar-H), 2958 (C-H), 1720 (C=O), 1607 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 0.82$ (d, J = 8 Hz, 6 H, 2 × CH₃), 1.51 (d, J = 8 Hz, 3 H, CH₃), 1.74 – 1.81 (m, 1 H, CH), 2.33 (s, 3 H, Ar-CH₃), 2.38 (d, J = 8 Hz, 2 H, CH₂), 2.93 (dd, J = 16 Hz, 1 H), 3.40 (dd, J = 16, 8 Hz, 1 H), 4.19 (q, J = 4 Hz, 1 H, CH), 4.61 (dd, J = 8.7, 4 Hz, 1 H), 7.04 – 7.08 (m, 4 H, Ar-H), 7.10 – 7.25 (m, 4 H, 4-methylphenyl), 13.93 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 18.7$, 19.2, 20.4, 22.8, 30.5, 34.7, 38.2, 39.7, 126.4, 127.8, 129.2, 131.6, 141.2, 153.2, 168.6, 173.2, 179.6. – LC-MS: m/z (%) = 448 (58) [M]⁺. – C₂₅H₂₈N₄O₃S (448.5): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4f: M. p. 158 °C; yield 68 %. – IR (KBr): v = 3249 (NH), 3062 (Ar-H), 2976 (C-H), 1710 (C=O), 1604 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 0.83$ (d, J = 8 Hz, 6 H, 2 × CH₃), 1.52 (d, J = 8 Hz, 3 H, CH₃), 1.76 – 1.82 (m, 1 H, CH), 2.38 (d, J = 8 Hz, 2 H, CH₂), 2.92 (dd, J = 16 Hz, 1 H), 3.41 (dd, J = 16, 8 Hz, 1 H), 3.92 (s, 3 H, OCH₃), 4.19 (q, J = 4 Hz, 1 H, CH), 4.72 (dd, J = 8, 7, 4 Hz, 1 H), 7.04 (d, J = 8 Hz, 2 H, Ar-H), 7.08 (d, J = 8 Hz, 2 H, Ar-H), 7.34 – 7.44 (m, 4 H, 4-methoxyphenyl), 13.93 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 18.7$, 19.2, 22.8, 30.5, 35.3, 38.2, 39.7, 60.4, 126.2, 127.0, 128.8, 130.2, 140.0, 153.5, 168.4, 173.0, 179.6. – LC-MS: m/z (%) = 464 (63) [M]⁺. – C₂₅H₂₈N₄O₃S (464.5): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4g: M. p. 152 °C; yield 83 %. – IR (KBr): v = 3216 (NH), 3048 (Ar-H), 2964 (C-H), 1704 (C=O), 1607 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 0.83$ (d, J = 8 Hz, 6 H, 2 × CH₃), 1.52 (d, J = 8 Hz, 3 H, CH₃), 1.76 – 1.82 (m, 1 H, CH), 2.38 (d, J = 8 Hz, 2 H, CH₂), 2.87 (dd, J = 16 Hz, 1 H), 3.39 (dd, J = 16, 8 Hz, 1 H), 4.19 (q, J = 4 Hz, 1 H, CH), 4.66 (dd, J = 8.7, 4 Hz, 1 H), 7.04 (d, J = 8 Hz, 2 H, Ar-H), 7.08 (d, J = 8 Hz, 2 H, Ar-H), 7.34 – 7.44 (m, 4 H, 4-bromophenyl), 14.00 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 18.6$, 19.3, 22.8, 30.4, 34.5, 37.6, 40.3, 126.2, 127.4, 129.4, 130.1, 140.2, 153.2, 168.8, 173.4, 179.5. – LC-MS: m/z (%) = 512 (62) [M]⁺, 514 (62) [M]⁺. – C₂₄H₂₅N₄O₂BrS (513.4): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4h: M.p. 157 °C; yield 78%. – IR (KBr): v = 3334 (NH), 3062 (Ar-H), 2924 (C-H), 1711 (C=O), 1599 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 2.42$ (s, 3 H, SCH₃), 2.89 (dd, J = 16 Hz, 1 H), 3.39 (dd, J = 16, 8 Hz, 1 H), 3.98 (s, 2 H, CH₂), 4.62 (dd, J = 8.7, 4 Hz, 1 H), 7.12 – 7.23 (m, 5 H, Ar-H), 7.41 – 7.48 (m, 4 H, phenyl), 14.00 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 16.1$, 32.3, 35.2, 41.2, 124.3, 127.5, 128.5, 129.9, 139.9, 152.1, 167.0, 172.7, 177.8. – LC-MS: m/z (%) = 410 (78) [M]⁺. – C₂₀H₁₈N₄O₂S₂ (410.5): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4i: M. p. 160 °C; yield 72 %. – IR (KBr): v = 3107 (NH), 3017 (Ar-H), 2920 (C-H), 1712 (C=O), 1596 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 2.41$ (s, 3 H, SCH₃), 2.85 (dd, J = 16 Hz, 1 H), 3.38 (dd, J = 16, 8 Hz, 1 H), 3.97 (s, 2 H, CH₂), 4.62 (dd, 1 H, J = 8.7, 4 Hz), 7.12 – 7.18 (m, 4 H, Ar-H), 7.20 – 7.55 (m, 3 H, 3-chloro-4-fluorophenyl), 13.99 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 16.1$, 32.3, 35.8, 40.2, 127.6, 128.5, 128.7, 130.8, 139.2, 140.5, 152.1, 167.0, 172.8, 177.7. – LC-MS: m/z (%) = 462 (69) [M]⁺, 464 (23) [M]⁺. – C₂₀H₁₆N₄O₂CIFS₂ (462.9): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4j: M. p. 182 °C; yield 68 %. – IR (KBr): v = 3319 (NH), 3056 (Ar-H), 2923 (C-H), 1711 (C=O), 1603 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 2.43$ (s, 3 H, SCH₃), 2.86 (dd, J = 16 Hz, 1 H), 3.38 (dd, J = 16, 8 Hz, 1 H), 3.98 (s, 2 H, CH₂), 4.60 (dd, J = 8.7, 4 Hz, 1 H), 7.14 – 7.24 (m, 4 H, Ar-H), 7.29 – 7.33 (m, 4 H, 4-fluorophenyl), 14.01 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 16.2$, 32.1, 35.3, 40.7, 127.5, 128.1, 129.1, 129.4, 140.4, 152.1, 167.0, 172.7, 177.5. – LC-MS: m/z (%) = 428 (64) [M]⁺. – C₂₀H₁₇N₄O₂FS₂ (428.5): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4k: M. p. 171 °C; yield 80 %. – IR (KBr): v = 3248 (NH), 3084 (Ar-H), 2978 (C-H), 1713 (C=O), 1614 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 2.48$ (s, 3H, SCH₃), 2.85 (dd, J = 16 Hz, 1 H), 3.38 (dd, J = 16, 8 Hz, 1 H), 4.01 (s, 2 H, CH₂), 4.61 (dd, J = 8.7, 4 Hz, 1 H), 7.12 – 7.16 (m, 4 H, Ar-H), 7.34 – 7.38 (m, 4 H, 4-chlorophenyl), 13.94 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 16.2$, 32.3, 35.2, 40.9, 126.5, 127.2, 128.4, 129.2, 140.8, 151.2, 167.1, 172.9, 177.3. – LC-MS: m/z (%) = 444 (75) [M]⁺, 446 (25) [M]⁺. – C₂₀H₁₇N₄O₂ClS₂ (444.9): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4l: M. p. 130 °C; yield 76%. – IR (KBr): v = 3308 (NH), 3067 (Ar-H), 2965 (C-H), 1709 (C=O), 1603 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 2.33$ (s, 3 H, Ar-

CH₃), 2.41 (s, 3 H, SCH₃), 2.86 (dd, J = 16 Hz, 1 H), 3.38 (dd, J = 16, 8 Hz, 1 H), 3.98 (s, 2 H, CH₂), 4.62 (dd, J = 8.7, 4 Hz, 1 H), 7.10–7.16 (m, 4 H, Ar-H), 7.29–7.33 (m, 4 H, 4-methylphenyl), 13.97 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 16.2$, 21.6, 32.4, 35.2, 40.6, 126.8, 127.6, 128.6, 129.4, 141.3, 151.4, 167.2, 172.2, 177.5. – LC-MS: m/z (%) = 424 (61) [M]⁺. – C₂₁H₂₀N₄O₂S₂ (424.5): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4m: M. p. 138 °C; yield 79 %. – IR (KBr): v = 3304 (NH), 3086 (Ar-H), 2927 (C-H), 1715 (C=O), 1608 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 2.50$ (s, 3 H, SCH₃), 2.87 (dd, J = 16 Hz, 1 H), 3.38 (dd, J = 16, 8 Hz, 1 H), 3.85 (s, 3 H, OCH₃), 4.02 (s, 2 H, CH₂), 4.61 (dd, J = 8.7, 4 Hz, 1 H), 7.08 – 7.14 (m, 4 H, Ar-H), 7.36 – 7.42 (m, 4 H, 4-methoxyphenyl), 13.94 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 16.2$, 32.3, 35.2, 40.8, 61.5, 127.2, 127.9, 129.2, 130.4, 140.6, 151.4, 168.1, 172.6, 177.9. – LC-MS: m/z (%) = 440 (68) [M]⁺. – C₂₁H₂₀N₄O₃S₂ (440.5): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

4n: M. p. 170 °C; yield 68 %. – IR (KBr): v = 3284 (NH), 3042 (Ar-H), 2926 (C-H), 1705 (C=O), 1598 (C=N) cm⁻¹. – ¹H NMR ([D₆]DMSO): $\delta = 2.50$ (s, 3 H, SCH₃), 2.86 (dd, J = 16 Hz, 1 H), 3.38 (dd, J = 16, 8 Hz, 1 H), 4.02 (s, 2 H, CH₂), 4.61 (dd, J = 8.7, 4 Hz, 1 H), 7.08 – 7.14 (m, 4 H, Ar-H), 7.36 – 7.42 (m, 4 H, 4-bromophenyl), 13.94 (s, 1 H, NH). – ¹³C NMR ([D₆]DMSO): $\delta = 16.1$, 32.2, 35.2, 41.1, 126.2, 127.1, 128.4, 129.8, 140.2, 151.4, 168.0, 172.4, 177.6. – LC-MS: m/z (%) = 488 (58) [M]⁺, 490 (58) [M]⁺. – C₂₀H₁₇N₄O₂BrS₂ (489.4): calcd. C 70.87, H 9.15, N 12.72; found C 70.85, H 9.13, N 12.70.

Acknowledgements

The authors are thankful to the Director, IISE Bangalore and CDRI Lucknow for ¹H NMR, ¹³C NMR, mass and IR data. M. K. is grateful to UGC for providing financial assistance under the UGC-RFSMS scheme.

- [1] S. Kawail, F. Kojima, N. Kusunoki, *Allergol. Int.* 2005, 54, 209 – 215.
- [2] G. D. Klasser, J. Epstein, J. Can. Dent. Assoc. 2005, 71, 575 – 580.
- [3] S. S. Adams, *Inflammopharmacology* **1999**, *7*, 191–
- [4] D. Ormrod, K. Wellington, A. Wagstaff, J. Drugs 2002, 62, 2059 – 2071.
- [5] G. Dannhardt, W. Keifer, Eur. J. Med. Chem. 2001, 36, 109 – 126.
- [6] L. Mernett, A. Kalgutkar, Trends Pharmacol. Sci. 1999, 20, 465 – 469.
- [7] M. C. Allison, A. G. Howatson, C. J. Torrance, F. D. Lee, R. I. Russell, N. Engl. J. Med. 1992, 327, 749 – 754.

- [8] M. B. Kimmey, J. Rheumatol. 1992, 19, 68-73.
- [9] J. J. Tally, R. S. Bertenshaw, D. L. Brown, J. S. Carter, M. J. Graneto, M. S. Kellogg, C. M. Kobolt, J. Yuan, Y. Y. Zhang, K. Seibert, J. Med. Chem. 2000, 43, 1661 – 1663.
- [10] D.J. Prasad, M. Ashok, P. Karegoudar, B. Poojary, B.S. Holla, N.S. Kumari, Eur. J. Med. Chem. 2000, 44, 551-557.
- [11] T. Karabasanagouda, A. V. Adhikari, M. Girisha, *Ind. J. Chem.* 2009, 48 B, 430 437.
- [12] M. Ashok, B. Shivarama Holla, *Phosphorus, Sulfur and Silicon* **2007**, *182*, 1599 1608.
- [13] T. Karabasanagouda, A. V. Adhikari, N. S. Shetty, Phosphorus, Sulfur and Silicon 2007, 182, 2925— 2941.

- [14] M. S. Karthikeyan, Eur. J. Med. Chem. 2009, 44, 827 833.
- [15] K. Walczak, A. Gondela, J. Suwinski, Eur. J. Med. Chem. 2004, 39, 849 – 853.
- [16] Y. Kawashima, H. Ishikawa, S. Kida, T. Tanaka, T. Masuda, *Japan Kokai* 1986, 61, 260085; *Chem. Abstr.* 1987, 106, 138475x.
- [17] The Merk Index, 12th Ed., Merk and Co. Inc., White-house Station, N. J., 1996.
- [18] J. Haber, Cas. Lek. Cesk. 2001, 140, 596-604.
- [19] A. Brucato, A. Copoola, S. Gianguzza, P.M. Provenzano, *Bull. Soc. Ital. Sper.* 1978, 54, 1051–1053.
- [20] D. L. Coffen, R. I. Fryer, U. S. Pat. 3,849, 434, 1974; Chem. Abstr. 82730044v. 1973.
- [21] M. Shiroki, Y. Tahara, K. Araki, Jap. Pat. 75100096, 1975
- [22] F.D. Povelista, A.G. Gural, *Antibiotiki (Moscow)* **1973**, *18*, 71; *Chem. Abstr.* **1973**, 78, 93044.
- [23] R. W. Sidwell, L. B. Allen, J. H. Hoffman, J. T. Witkowsti, L. N. Simon, *Proc. Soc. Exp. Biol. Med.* 1975, 148, 854–858.
- [24] K. K. Vijaya Raj, B. Narayana, B. V. Ashalatha, N. S. Kumari, B. K. Sarojini, Eur. J. Med. Chem. 2007, 42, 425–429.

- [25] B. S. Holla, K. V. Malini, B. S. Rao, B. K. Sarojini, Eur. J. Med. Chem. 2003, 38, 313 – 318.
- [26] B. Jiang, X. H. Gu, Bioorg. Med. Chem. Lett. 2000, 8, 363–371.
- [27] E. Medime, G. Capan, Il Farmaco 1994, 49, 449 451.
- [28] F. Bordi, P.L. Catellani, G. Morinha, P.V. Plazzi, C. Silva, E. Barocelli, M. Chiavarini, *Il Farmaco* 1989, 44, 795–805.
- [29] R. Lesyk, O. Vladzimirska, S. Holota, L. Zaprutko, A. Gzella, Eur. J. Med. Chem. 2007, 42, 641 – 648.
- [30] D. Lednicer, L. A. Mitscher, G. I. George, *Organic Chemistry of Drug Synthesis*, Vol. 4, Wiley, New York, 1990, pp. 95 97.
- [31] M. Z. Rehman, C. J. Anwar, S. Ahmad, Bull. Korean Chem. Soc. 2005, 26, 1771 – 1775.
- [32] M. P. Knadlar, R. F. Bergstrom, J. T. Callaghan, A. Rubin, *Drug Metab. Dispos.* 1986, 14, 175 – 182.
- [33] M. S. Karthikeyan, B. S. Holla, Monatsh. Chem. 2008, 139, 691 – 696.
- [34] M. Cava, A. Deana, K. Muth, M. Mitchell in *Organic Syntheses*, Coll. Vol. 5 (Ed.: H. E. Baumgarten), Wiley, New York, **1973**, pp. 944.
- [35] T. Takahashi, Tetrahedron Lett. 1964, 11, 565 572.